/SMMT
SMMT Stock - Summit Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$17.82+4.58%
+$0.78 (+4.58%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+38.4%upside
Target: $24.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SMMT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$17.64 – $18.00
TARGET (TP)$24.67
STOP LOSS$16.39
RISK/REWARD1:4.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.53
52W High$36.91
52W Low$15.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $704,295 | $1.81M | $860,000 |
| Gross Profit | $-15,007,000 | $-2,050,000 | $-1,810,000 | $1.81M | $860,000 |
| Gross Margin | N/A | N/A | -257.0% | 100.0% | 100.0% |
| Operating Income | $313,000 | $-89,736,000 | $-59,633,000 | $-86,186,000 | $-53,193,000 |
| Net Income | $-221,315,000 | $-614,928,000 | $-78,782,000 | $-88,602,000 | $-52,697,000 |
| Net Margin | N/A | N/A | -11185.9% | -4897.8% | -6127.6% |
| EPS | $-0.31 | $-0.99 | $-0.41 | $-0.96 | $-0.76 |
Company Overview
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
73%
Hold / Neutral
3
20%
Sell / Underperform
1
7%
Analyst Consensus🟢 Bullish
11 Bullish4 Neutral/Bearish
Price Targets
$25
Average Target
↑ 39.6% Upside
Now
$7
Low
$25
Average
$42
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | Barclays | Upgrade | Equal Weight | $18 |
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| September 17th 2025 | Barclays | Initiation | Underweight | $13 |
| September 4th 2025 | Guggenheim | Initiation | Buy | $40 |
| August 19th 2025 | Piper Sandler | Initiation | Neutral | $21 |
| July 1st 2025 | UBS | Initiation | Buy | $30 |
| June 11th 2025 | Leerink Partners | Initiation | Underperform | $12 |
| March 26th 2025 | Citigroup | Upgrade | Buy | $35← $23 |
| March 21st 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| March 12th 2025 | Evercore ISI | Initiation | Outperform | $30 |
| February 28th 2025 | Goldman | Initiation | Buy | $42 |
| January 8th 2025 | Truist | Initiation | Buy | $35 |
| December 11th 2024 | Wells Fargo | Initiation | Overweight | $30 |
| December 6th 2024 | Jefferies | Initiation | Buy | $31 |
| November 4th 2024 | JMP Securities | Initiation | Mkt Outperform | $32 |
Earnings History & Surprises
SMMTBeat Rate
62%
Last 13 quarters
Avg Surprise
-44.2%
EPS vs Estimate
Beats / Misses
8/4
1 met exactly
Latest EPS
$-1.04
Q3 2025
EPS Surprise History
Q4 23
No data
Q2 24
0.0%
$-0.06vs$-0.06
Q3 24
+16.7%
$-0.05vs$-0.06
Q4 24
-14.3%
$-0.08vs$-0.07
Q1 25
+2.2%
$-0.08vs$-0.08
Q2 25
+3.2%
$-0.09vs$-0.09
Q3 25
-736.9%
$-0.76vs$-0.09
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $-0.22 | — | — | — |
Q3 2025 | Aug 11, 2025 | — | $-1.04 | — | — |
Q3 2025 | Aug 11, 2025 | $-0.09 | $-0.76 | -736.9% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.09 | $-0.09 | +3.2% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.08 | $-0.08 | +2.2% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.06 | $-0.06 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | — | $-0.03 | — | — |
Q3 2023 | Aug 9, 2023 | — | $-0.02 | — | — |
Q2 2023 | May 11, 2023 | — | $-0.06 | — | — |
Q1 2023 | Mar 9, 2023 | $-0.26 | $-0.07 | +73.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.26 | $-0.14 | +46.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.27 | $-0.17 | +37.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.28 | $-0.22 | +21.4% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.27 | $-0.28 | -3.7% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.29 | $-0.20 | +31.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.18 | $-0.27 | -50.0% | ✗ MISS |
Q2 2021 | May 17, 2021 | — | $-1.05 | — | — |
Latest News
Barclays Upgrades Summit Therapeutics to Equal-Weight, Raises Price Target to $18
📈 PositiveBenzinga•Dec 17, 2025, 02:45 PM•Also:
Wolfe Research Initiates Coverage On Summit Therapeutics with Peer Perform Rating
➖ NeutralBenzinga•Nov 18, 2025, 05:14 PM
Summit Therapeutics Partner Akeso Publishes Results From Phase III HARMONi-A Trial Showing Statistically Significant OS Benefit
📈 PositiveBenzinga•Nov 7, 2025, 02:10 PM•Also:
Summit Therapeutics To Present Phase III Lung Cancer Trial Results For Ivonescimab At SITC 2025
➖ NeutralBenzinga•Oct 31, 2025, 11:04 AM
Summit Therapeutics Files For Shelf Of Up To 26.7M Shares Of Common Stock By Selling Stockholders
📉 NegativeBenzinga•Oct 29, 2025, 09:19 PM
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 22, 2025, 01:14 PM
Summit Therapeutics Accepts Offers From Investors to Purchase ~26.68M Shares At $18.74/Share, Raising $500M In Proceeds
📈 PositiveBenzinga•Oct 22, 2025, 12:04 PM
Summit Therapeutics shares are trading lower after HC Wainwright maintained a Buy rating on the stock but lowered its price target from $50 to $40.
📉 NegativeBenzinga•Oct 21, 2025, 02:18 PM
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
➖ NeutralBenzinga•Oct 21, 2025, 12:50 PM•Also:
HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40
➖ NeutralBenzinga•Oct 21, 2025, 11:08 AM
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $40
📈 PositiveBenzinga•Oct 20, 2025, 03:33 PM•Also:
JMP Securities Reiterates Market Outperform on Summit Therapeutics, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 01:39 PM
Summit Therapeutics shares are trading lower following Q3 financil results. The company announced plans to submit a Biologics License Application in order to seek approval for ivonescimab plus chemotherapy for this proposed indication.
📉 NegativeBenzinga•Oct 20, 2025, 12:38 PM
Summit Therapeutics Q3 Adj. EPS $(0.13), Inline
➖ NeutralBenzinga•Oct 20, 2025, 10:52 AM
Summit Therapeutics Said That Based On HARMONi Trial Data, It Plans To Submit A Biologics License Application For Ivonescimab Plus Chemotherapy For Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer In Q4 Of 2025
📈 PositiveBenzinga•Oct 20, 2025, 10:48 AM
Reported Sunday, Summit Announces Ivonescimab Achieved Median Progression-Free Survival Of 11.14 Months Compared To 6.90 Months For Tislelizumab Plus Chemotherapy In Landmark HARMONi-6 Trial
📈 PositiveBenzinga•Oct 20, 2025, 07:16 AM
Summit Therapeutics Initiates Global Phase III HARMONi-GI3 Trial Evaluating Ivonescimab Plus Chemotherapy In Metastatic Colorectal Cancer
📈 PositiveBenzinga•Oct 17, 2025, 11:04 AM
Summit Therapeutics shares are trading higher after the company announced data from the Phase III HARMONi-6 trial.
📈 PositiveBenzinga•Sep 24, 2025, 02:31 PM
Summit Therapeutics' HARMONi-6 Phase III Trial Shows Ivonescimab Plus Chemotherapy Significantly Improves PFS Over Tislelizumab In 1L Squamous NSCLC; Data To Be Presented At ESMO 2025 Presidential Symposium
📈 PositiveBenzinga•Sep 24, 2025, 11:04 AM
Barclays Initiates Coverage On Summit Therapeutics with Underweight Rating, Announces Price Target of $13
📉 NegativeBenzinga•Sep 17, 2025, 11:00 AM•Also:
Frequently Asked Questions about SMMT
What is SMMT's current stock price?
Summit Therapeutics Inc. (SMMT) is currently trading at $17.82 per share. The stock has moved +4.58% today.
What is the analyst price target for SMMT?
The average analyst price target for SMMT is $24.67, based on 1 analyst.
What sector is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SMMT's market cap?
Summit Therapeutics Inc. has a market capitalization of $13.27 billion, making it a large-cap company.
Does SMMT pay dividends?
No, Summit Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASND
Ascendis Pharma A/S
$199.99
Mkt Cap: $12.1B
BBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
EXAS
Exact Sciences Corporation
$101.82
Mkt Cap: $19.3B
IONS
Ionis Pharmaceuticals, Inc.
$79.57
Mkt Cap: $12.6B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
RPRX
Royalty Pharma plc
$38.60
Mkt Cap: $16.8B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
UHS
Universal Health Services, Inc.
$227.46
Mkt Cap: $14.7B
Explore stocks similar to SMMT for comparison